Last updated: February 26, 2026
What is the Indicated Use and Market Scope?
NDC 63481-0629 corresponds to Nivolumab (Opdivo), a PD-1 immune checkpoint inhibitor approved for multiple cancer indications. Approved indications include melanoma, non-small cell lung cancer (NSCLC), renal cell carcinoma, and others.
Estimated global sales for nivolumab reached approximately $8.8 billion in 2022.[1] The drug's market is expanding with approvals for new indications such as head and neck squamous cell carcinoma and previously untreated mesothelioma.
What are the Key Drivers and Competitive Landscape?
Market Drivers:
- Increasing cancer prevalence, especially NSCLC and melanoma.
- Expanding indication approvals.
- Growing reimbursement and regulatory support.
- Combination therapies with nivolumab, enhancing efficacy but increasing cost.
Competitive Landscape:
- Major competitors include pembrolizumab (Keytruda), atezolizumab (Tecentriq), and durvalumab (Imfinzi).
- Pembrolizumab maintains the largest market share, with over $15 billion in 2022 sales.[2]
- Nivolumab holds roughly 25-30% of the PD-1/PD-L1 inhibitor market.
Price Trends:
- List prices vary by indication and dosage but are approximately $150,000 to $180,000 per year for monotherapy in the U.S.
- Price adjustments have been minimal due to longstanding patent exclusivity and patent extensions.
What are the Regulatory and Patent Factors?
- Patent protection for nivolumab extends into the late 2020s with known patent expirations on the original formulations.
- Patent challenges and biosimilar entries are anticipated by 2028, potentially affecting pricing.
- Regulatory approvals continue to expand indications, sustaining market demand.
How Are Pricing and Market Share Expected to Change?
| Year |
Estimated Global Sales |
Price Range (USD/year) |
Key Factors |
| 2022 |
$8.8 billion |
$150,000–$180,000 |
Stable demand, limited biosimilar competition in the U.S. |
| 2023 |
$9.2–$9.5 billion |
Same as 2022 |
New indications and ongoing expansion in Asia |
| 2024 |
$9.5–$10 billion |
Potential slight decrease |
Biosimilar entries in E.U. and other markets may initiate price compression |
| 2025 |
$10–$11 billion |
Price pressures increase |
Biosimilars entering U.S. market, discount negotiations |
| 2028 |
$7–$8 billion |
Price declines expected |
Biosimilar competition peaks, patent expirations |
What are the Price Projection Assumptions?
- In the short term, list prices remain stable due to patent protections.
- Cost reductions from biosimilar competition are projected to lower net prices by 20-30% once biosimilars gain market share.
- Volume increases driven by regulatory approvals could offset price declines, maintaining overall revenue growth until biosimilar impact intensifies.
What Are the Risks to Market and Price Projections?
- Accelerated biosimilar development and market entry.
- Price negotiations and reimbursement restrictions.
- New competing therapies with superior efficacy or safety profiles.
- Changes in regulatory policies impacting the approval or reimbursement landscape.
Summary of Key Data Points
- Nivolumab (Opdivo) revenues: recent fiscal year approximately $8.8 billion.
- U.S. list price: around $150,000–$180,000/year.
- Major competitors: Pembrolizumab (Keytruda), atezolizumab (Tecentriq).
- Market share: Nivolumab holds 25–30% of PD-1/PD-L1 class.
- Patent expiration: late 2020s; biosimilar impact expected 2028.
Key Takeaways
- Nivolumab remains a leading immune checkpoint inhibitor with high revenue streams.
- Market growth driven by expanding indications and geographic penetration.
- Price stability is expected until biosimilar competition increases circa 2028.
- Forecasted market revenue could decline 25–30% post-biosimilar entry.
- Strategic considerations include patent management, indication expansion, and biosimilar preparedness.
FAQs
1. How will biosimilar competition impact nivolumab pricing?
Biosimilar entry from 2028 is projected to lower net prices by 20–30%, significantly reducing revenue unless offset by increased volumes or new indications.
2. Are there upcoming regulatory approvals that could boost demand?
Yes, ongoing trials and approvals for indications such as small cell lung cancer, mesothelioma, and combination therapies could boost future sales.
3. What markets besides the U.S. are important for nivolumab?
Europe, China, Japan, and emerging markets show strong growth potential due to expanding cancer treatment access.
4. How does nivolumab’s patent status influence pricing?
Patent protections until the late 2020s maintain exclusivity, supporting stable or increasing prices until biosimilar competition begins.
5. What are strategic considerations for investors?
Monitoring patent timelines, biosimilar developments, and expanding indications is critical for valuation adjustments and market entry strategies.
References
[1] IQVIA. (2023). Global Oncology Market Reports.
[2] EvaluatePharma. (2022). Oncology Revenue Data.
[3] FDA. (2022). Approval and Indication Announcements.
[4] BioPharmadive. (2022). Biosimilar Market Entry and Impact.
[5] MarketWatch. (2023). Pharma Pricing Trends.
